Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biotronik reports new clinical data showing efficacy of Orsiro stent

Biotronik reports new clinical data showing efficacy of Orsiro stent

2nd June 2016

Biotronik has announced new clinical trial data that adds to the body evidence supporting the effectiveness of its Orsiro hybrid drug-eluting stent.

The ORIENT trial enrolled 372 patients, who were treated with either the Orsiro or Resolute Integrity stents for a wide variety of coronary heart disease.  Orsiro demonstrated significant non-inferiority to Resolute Integrity in terms of in-stent late lumen loss after nine months.

Further results from the trial highlighted Orsiro's excellent safety profile, with no stent thrombosis observed. This underlines the viability of the Orsiro stent as a viable alternative to Resolute Integrity.

This comes after results from the previous BIOSCIENCE study demonstrated the benefits the Biotronik device can provide compared to a leading comparator product.

Dr Alexander Uhl, vice-president for marketing at Biotronik's vascular intervention, said: "As our robust clinical programme continues to drive clinical acceptance worldwide, Orsiro has already benefited half a million of patients."

This comes after the firm recently commenced a new study called BIOSTEMI, which aims to assess the effectiveness of Orsiro in treating ST-segment elevation myocardial infarction patients.ADNFCR-8000103-ID-801819645-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.